Risky work in pharmaceutical companies. Ed

lettera_di_licenziamentoLetter of dismissal for 176 employees of Boehringer Italy. Just a year ago, from its headquarters in Germany, the pharmaceutical group announced a drastic reduction in personnel by 2016. Now, we are at the facts. And it starts with us, from Milan.

The tile on the head reaches employees and scientific collaborators of the headquarters in via Lorenzini che from January they will stay at home. "The reasons are connected to the sharp cuts in healthcare spending - explains a company press release - and in particular to the criticality of the Prescription Medicine division on which the 75% of turnover depends: in recent years, it has recorded a sharp decline".

Already. Apart from the sanctions ready to be triggered for general practitioners who want to make sure of the patient's status with specialist visits, x-rays, CT scans, MRIs, laboratory tests and allergy tests... even on drugs there has been a big crackdown.

“My doctor, for bronchitis, recommended an alternative drug to me – says a lady in her 40s -: the loanable one, well known, which I had recently taken, is no longer on the market. Only this one costs 20 euros. And it's at my expense."

Sthere is the breakthrough on medicines. If on the one hand Aifa has published all those who have moved from band A (fully paid by the NHS) to band C (paid by the patient) ... and amen, there is also a different type of phenomenon that is increasingly advancing . Patients are diverted to take medical devices, supplements, parapharmaceuticals, homeopathic remedies.

But not only from family doctors, but also from pharmacists… who suggest (and recommend!) non-prescribable alternatives. And expensive. All to the detriment of 'traditional' pharmaceutical companies.

In addition to the Boehringer crisis, in fact (which is supported by Assolombarda and in recent days has welcomed union representatives together with CGIL, CISL and UIL to try to find an agreement), there are troubled waters at the home of many pharma giants: the the American Pfizer would like to strengthen itself with the merger with the Irish Allergan; the (alas, usual) Glaxo of Verona has announced the mobility of 60 employees; Abbot-AbbVie of Latina will fire 27 of them.

In short, other people without work. But in recent weeks, there has been no talk of a trend reversal, of data that mark the 11.8% of unemployed with a drop of 8.1%?

twitter@laurabonani

6 novembre 2015 – Laura Bonani – La Nuvola del Lavoro Corriere

Related news: The slow decline of pharmaceutical whistleblowers

Farm industry. Pharmaceuticals: Italy takes the lead in export growth, driving production

Farmaceutica: Scaccabarozzi, avremo ‘tsunami’ farmaci innovativi

Farmaceutica, continua l’aumento dell’occupazione: +1% prima metà 2015

13,400 jobs lost in seven years. The union between a rock and a hard place

Ed.: Between 2004 and 2014, "medicines and pharmaceutical preparations" recorded the greatest growth among all sectors of the economy: +11 billion euros (source: Istat IMS).

Exports represent 72% of turnover, with strong growth compared to 10 years ago (46%)

At the same time, R&D is lower than that of the main European countries and, in the period 2007/2014, fired 13,400 informants.  

Furthermore, doctors can recommend non-reimbursed products to escape the threats of the various ASLs on the spending budgets assigned to them.

Everyone draws the conclusions they deem most appropriate.

Exit mobile version